← All Transcode Therapeutics, INC filings

Transcode Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
RNAZ
Transcode Therapeutics, INC
10-K/A: TransCode Therapeutics 10-K/A Filing Update
TransCode Therapeutics files an amendment to its 2025 Annual Report to include required Part III disclosures.
NASDAQ
RNAZ
Transcode Therapeutics, INC
10-K: TransCode Therapeutics Finalizes Key Licensing and Financing Deals
TransCode Therapeutics, Inc. has entered into a significant equity issuance and registration rights agreement with Unleash Immuno Oncolytics, Inc., alongside a standby equity purchase agreement with YA II PN, LTD, bolstering its financial and strategic position.
NASDAQ
RNAZ
Transcode Therapeutics, INC
10-K/A: TransCode Therapeutics Files Amendment to 10-K, Updates Director and Executive Information
TransCode Therapeutics files an amendment to its 2024 Annual Report on Form 10-K to include previously omitted information regarding directors, executive officers, and corporate governance.
NASDAQ
RNAZ
Transcode Therapeutics, INC
10-K: TransCode Therapeutics Navigates Financial Challenges While Advancing RNA Oncology Pipeline
TransCode Therapeutics faces financial hurdles but progresses with clinical trials and preclinical programs in RNA-based cancer therapies.
NASDAQ
RNAZ
Transcode Therapeutics, INC
10-K: TransCode Therapeutics Files 10-K, Details Progress on RNA Oncology Platform
TransCode Therapeutics' 10-K filing highlights the company's progress in developing its RNA oncology platform, including its lead candidate TTX-MC138, and its financial position.